Abstract Library

#1941 Integrated Safety Analysis of Telotristat Ethyl in Patients with Carcinoid Heart Disease

Introduction: Release of serotonin by neuroendocrine tumors is associated with carcinoid heart disease (CaHD), which may pose challenges for carcinoid syndrome (CS) treatment.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lapuerta P

Authors: Lapuerta P, Kulke M, Pavel M, Biran T, Fleming R,

Keywords: serotonin, 5-HIAA,

#1812 Correlation of Plasma (p) and Urine (u) 5-HIAA Levels in Patients (pts) with Carcinoid Syndrome (CS) – Post-Hoc Analyses from the TELESTAR Study

Introduction: Telotristat ethyl (TE) is an oral tryptophan hydroxylase inhibitor in development for treating CS symptoms. During the double-blind treatment [DBT] period of the phase 3, 12-week, placebo-controlled TELESTAR study, TE was well tolerated and significantly reduced bowel-movement frequency and u5-HIAA levels compared with placebo (PBO) in NET patients with CS treated with a SSA.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Pavel M, Hörsch D, Hoffmanns P, Biran T, Houchard A,

Keywords: carcinoid syndrome, 5-HIAA, telotristat,

#1501 Inhibition of Intestinal Neuroendocrine Tumor by a New Marker of Normal Neuroendocrine Cells

Introduction: Although gastrointestinal neuroendocrine tumors are increasing worldwidely, few treatment options could be chosen

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Guo Y

Authors: Pan B, Yang W, Zhang T, Guo Y,

Keywords: GEP-NETs, Wnt, marker,